Diamond Sponsor
Platinum Sponsors
Silver Sponsors
Bronze Sponsor
Diamond Sponsor

Guardant
Read Company Description
Guardant Health is a leading precision oncology company focused on helping conquer cancerglobally through use of its proprietary tests, vast data sets and advanced analytics.
Theoncology platform leverages capabilities to drive commercial adoption, improve patient clinicaloutcomes and lower healthcare costs across all stages of the cancer care continuum.
Theoncology platform leverages capabilities to drive commercial adoption, improve patient clinicaloutcomes and lower healthcare costs across all stages of the cancer care continuum.
Platinum Sponsors

Foundation Medicine
Read Company Description
Foundation Medicine’s highly validated portfolio of comprehensive genomic profiling testsprovides clinically-relevant genomic results for all advanced cancer patients regardless ofspecimen type. Find out more about the first FDA-approved test for solid tumors, our liquidbiopsy for solid tumors, and our test for hematologic malignancies at foundationmedicine.com/genomic-testing.
Silver Sponsors

Menarini Silicon Biosystems
Read Company Description
Menarini Silicon Biosystems offers the new CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration assay, the first-of-its-kind LDT, which directly measures levels of plasma cells in peripheral blood. The CELLSEARCH® CMMC enumeration test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, the test serially monitors plasma cell burden over time without requiring repeated bone marrow biopsies. Through our groundbreaking technology platforms and global lab services, we have standardized serial monitoring through cell-based liquid biopsy for a variety of conditions.

Natera
Read Company Description
Signatera is a personalized, tumor-informed ctDNA assay for molecular residual disease (MRD) detection and treatment response monitoring in patients previously diagnosed with cancer. Signatera is optimized to detect low levels of ctDNA, to help stratify high risk patients and optimize patient management. Discover more at: www.natera.com/oncology/signatera-advanced-cancer-detection/

EMD Serono
Read Company Description
Merck KGaA, Darmstadt, Germany is a science-led organization dedicated to making a meaningful difference in the lives of people affected by cancer. Our oncology research aims to leverage our synergistic portfolio to tackle challenging tumor types, as we work to illuminate a path to scientific breakthroughs to transform patient outcomes. Learn more at www.merckgrouponcology.com
Bronze Sponsor

Bio-Rad Laboratories
Read Company Description
Bio-Rad is a global leader for life science research and clinical diagnostics that advance several applications for liquid biopsy. For assessing cfDNA and ctDNA in liquid biopsies, Droplet Digital PCR (ddPCR) offers unrivaled detection, precision, and absolute quantification. Celselect
Slide™ Technology with the Genesis System enables CTC enrichment and enumeration applications.
Slide™ Technology with the Genesis System enables CTC enrichment and enumeration applications.

Sermonix Pharmaceuticals
Read Company Description
Sermonix Pharmaceuticals Inc is a privately held biopharmaceutical company with a precision medicine focus for bringing targeted oncology products through development, approval, and commercialization. Sermonix’s Lasofoxifene, entering phase 3, is thought to be a potent
third-generation selective estrogen receptor modulator (SERM) with high affinity for the estrogen receptor 1 (ESR1).
third-generation selective estrogen receptor modulator (SERM) with high affinity for the estrogen receptor 1 (ESR1).

Blueprint Medicines
Read Company Description
Blueprint Medicines is a global precision therapy company that aims to invent life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. (US-BP-MED-NP-22031)

Genomics
Read Company Description
C2i Genomics deploys an innovative ctDNA MRD solution for personalized cancer detection and monitoring. C2i’s whole-genome technology provides ultra-high sensitivity with significantly reduced lab operation complexity, eliminate the need to develop a patient-specific assay, and allowing earlier detection of recurrent cancer, to inform better treatment decisions and improve outcomes.
HAVE A QUESTION
Please submit your question for this presentation here. Your question will be answered by the end of October.

Thank you for submitting your question.